Business Wire

Nomios Group Expands in Southern Europe with the Leading Italian Cybersecurity Expert Aditinet

Share

Nomios Group, a leading European provider of cybersecurity services and solutions, announced today that it has completed the acquisition of a majority stake in Aditinet, a prominent cybersecurity company in the Italian market. The acquisition strengthens Nomios’ European position as one of the leading cybersecurity service companies.

“This acquisition marks an important step in Nomios’ continued growth and success, and we see many benefits in terms of a shared vendor portfolio, customer relationship, and service offerings. Not only does the acquisition of Aditinet provide the Nomios Group with a significant expertise and strong customer base in Italy, but it also allows us to add new services such as ethical hacking to our portfolio” explained Sébastien Kher, CEO of Nomios Group.

With the addition of Aditinet, the Nomios Group annual revenue grows to EUR 400M, and its consolidated headcount grows to over 600 FTEs throughout its seven European markets. The current CEO and Founder (Paolo Marsella) and CFO (Alberto Mez) will remain minority shareholders and will continue to manage the company and will lead the integration within the Nomios Group.

“Becoming part of Nomios is the ideal next step in realising Aditinet’s vision of making IT and the cloud the most secure environment for our customers and in further consolidating our relationships with critical vendors” said Paolo Marsella, CEO of Aditinet. “Nomios will provide European scale and expertise to further accelerate our growth in the Italian market. We look forward to immediately take advantage of Nomios’ famous SOC capabilities to help monitor our customer’s security perimeters and rely on their many references in SASE. We see a lot of talks about these technologies in the market, and our new Nomios colleagues have already proven that they can deliver in both respects”.

About Nomios Group

Nomios is a leading European provider of cybersecurity and secure networking solutions and services and has a broad customer base in highly diversified sectors. In 19 years, Nomios has grown into an organisation with more than 20 offices in seven European countries and has continuously expanded its own professional services, managed services, support and SOC offering. Nomios has the most experienced, loyal and highly certified pool of engineers in its industry, as recognised by many third-party studies, and has strategic partnerships with leading technology providers, including Palo Alto Networks, Juniper Networks, Cisco, Fortinet, F5, and others. In January 2019, funds advised by IK Partners, a leading Pan-European private equity firm, acquired a majority stake in Nomios Group.

About Aditinet

Founded in 2004, Aditinet is an Italian system integration and professional services company specialising in cybersecurity. With an annual revenue of EUR 40 million, Aditinet is among the most recognised players in the Italian cybersecurity industry with best-in- class certifications with Palo Alto Networks (Diamond) and F5 (Platinum) among other highly ranked vendor partnerships. Aditinet has two main offices in Italy, namely in Rome and Milan. Aditinet serves over 150 customers, which include several Italian national banks, utility providers, universities, manufacturing companies and ministries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PR Contact TOP RP Philippe Grand – 33 6 72 73 32 49 – pgrand@toprp.fr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye